[go: up one dir, main page]

WO2024259345A3 - Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a - Google Patents

Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a Download PDF

Info

Publication number
WO2024259345A3
WO2024259345A3 PCT/US2024/034164 US2024034164W WO2024259345A3 WO 2024259345 A3 WO2024259345 A3 WO 2024259345A3 US 2024034164 W US2024034164 W US 2024034164W WO 2024259345 A3 WO2024259345 A3 WO 2024259345A3
Authority
WO
WIPO (PCT)
Prior art keywords
swi
snf
compounds
degrade
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/034164
Other languages
French (fr)
Other versions
WO2024259345A2 (en
Inventor
Geoffray LERICHE
Dange Vijay Kumar
Kevin D. Freeman-Cook
Simon Bailey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plexium Inc
Original Assignee
Plexium Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexium Inc filed Critical Plexium Inc
Publication of WO2024259345A2 publication Critical patent/WO2024259345A2/en
Publication of WO2024259345A3 publication Critical patent/WO2024259345A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are compounds of formula I, or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, that are useful for modulating or degrading protein which is expressed from one or more SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A (SMARCA) (e.g., SMARCA2 and/or SMARCA4).
PCT/US2024/034164 2023-06-16 2024-06-14 Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a Pending WO2024259345A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508804P 2023-06-16 2023-06-16
US63/508,804 2023-06-16

Publications (2)

Publication Number Publication Date
WO2024259345A2 WO2024259345A2 (en) 2024-12-19
WO2024259345A3 true WO2024259345A3 (en) 2025-01-23

Family

ID=93852794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/034164 Pending WO2024259345A2 (en) 2023-06-16 2024-06-14 Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a

Country Status (1)

Country Link
WO (1) WO2024259345A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180086720A1 (en) * 2015-02-25 2018-03-29 Genentech, Inc. Therapeutic compounds and uses thereof
WO2018232039A1 (en) * 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Methods for modifying rna splicing
US20200038378A1 (en) * 2018-04-01 2020-02-06 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2024086361A1 (en) * 2022-10-21 2024-04-25 Novartis Ag Molecular glue degrader compounds and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180086720A1 (en) * 2015-02-25 2018-03-29 Genentech, Inc. Therapeutic compounds and uses thereof
WO2018232039A1 (en) * 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Methods for modifying rna splicing
US20200038378A1 (en) * 2018-04-01 2020-02-06 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2024086361A1 (en) * 2022-10-21 2024-04-25 Novartis Ag Molecular glue degrader compounds and uses thereof

Also Published As

Publication number Publication date
WO2024259345A2 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
PH12022553603A1 (en) Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same
MX2024015753A (en) Pharmaceutical compositions comprising wrn helicase inhibitors
EP4595965A3 (en) Heteroalkyl dihydroquinoline sulfonamide compounds
ZA202201794B (en) Crystalline forms of cftr modulators
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
MX2025003420A (en) Pyrimidine-fused ring compound, and preparation method therefor and use thereof
WO2024120378A3 (en) Triazole compounds, preparation methods and medicinal uses thereof
MX2024015752A (en) Pharmaceutical compositions comprising wrn helicase inhibitors
PH12022551139A1 (en) 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity
CR20220148A (en) Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers
MX2024011317A (en) Processes for the preparation of substituted spirooxindole derivatives
WO2024238633A3 (en) Kras g12s and g12c inhibitors
WO2022104153A3 (en) Compounds and methods for treating viral infections
WO2024259345A3 (en) Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a
WO2024259341A3 (en) Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a
WO2024259336A3 (en) Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a
WO2022268935A3 (en) Process for the preparation of nlrp3 inhibitors
MX2024012470A (en) Cdk9 inhibitors
MX2023009954A (en) Aminopyrimidine compounds and methods of their use.
MX2022006104A (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor.
MX2025008424A (en) Lanifibranor formulation
WO2021071812A8 (en) Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers
MX2023000926A (en) NEW DERIVATIVE OF PYRAZOLE.
MX2023002288A (en) Protein secretion inhibitors.
MX2024010431A (en) Compound as fak inhibitor and use thereof.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AU2024305544

Country of ref document: AU